Skip to main content

Orzeyful (oveporexton) is now available in the U.S. for adults with narcolepsy type 1

WSCN welcomes an important development for the narcolepsy community. On November 12, 2026, Takeda announced that Orzeyful TM (oveporexton), first-of-its-kind treatment for adults with narcolepsy type 1 (NT1), is now available by prescription in the United States.

⁠For people living with NT1, symptoms can affect life across all 24 hours, from difficulty staying awake during the day to disrupted sleep at night. Cataplexy, a sudden and temporary loss of muscle tone, can add another challenge to daily life. Managing these symptoms can shape how people plan work, school, and everyday activities.

A new approach to treatment

Most existing treatments focus on managing symptoms. Orzeyful is the first FDA-approved treatment for NT1 that directly targets the loss of orexin signaling. It works by activating receptors in the brain to help restore signaling affected by the loss of orexin, a chemical that helps regulate wakefulness.

In clinical studies, adults who took Orzeyful were able to stay awake longer on a daytime wakefulness test, reported less daytime sleepiness, and had fewer episodes of cataplexy per week than adults who took a placebo.

At WSCN, we recognize this as an exciting breakthrough and a meaningful new treatment option for people living with NT1. It is an important step forward in our understanding of central disorders of hypersomnolence and how our brains regulate our sleep-wake cycles each day.

What comes next

Orzeyful is currently approved in the United States for adults with NT1 and can be accessed via a prescription from a licensed healthcare provider. Anyone interested in treatment should speak with their healthcare provider to see if Orezyful is a good fit, and benefits and side effects to consider.

Other hypersomnolence disorders

Orzeyful is not approved for treatment of narcolepsy type 2 (NT2) or idiopathic hypersomnia (IH). Further research is needed to understand whether orexin-based treatments may help people with these conditions, and other medicines are currently being investigated.